Press release

Biophytis announces its participation to the BIO-Europe Spring 2025 in Milan

Paris, France, Cambridge (Massachusetts, USA), March 5th 2025 – 7:00AM – Biophytis SA (Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, is pleased to announce its participation in BIO-Europe Spring 2025, taking place in Milan, Italy, from march 17 to 19, 2025.

Edouard Bieth, our Chief Business Officer, will take part in numerous meetings throughout the conference. As one of the most innovative biotechnology companies in aging, Biophytis is looking forward to connecting with industry leaders, partners and innovators to discuss the future of our lead drug candidate, BIO101 in obesity and sarcopenia.

About BIO-Europe Spring

In 2024, BIO-Europe brought together over 3,400 participants from 59 countries and more than 2,000 companies, making it the largest gathering of pharmaceutical industry professionals in Europe. For more information, visit www.informaconnect.com/bioeurope.

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for agerelated diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start, and Duchenne muscular dystrophy, Phase 1-2 to be started), respiratory diseases (COVID-19, Phase 2-3 completed), and metabolic disorders (obesity, Phase 2 to be started). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will

Press release

be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts Biophytis

Business Development and partnerships [email protected]

Relations Investisseurs [email protected]

US Investors Pascal Nigen – Alpha Bronze [email protected]

Media contacts

Antoine Denry: [email protected] – +33 6 18 07 83 27 Inès de Mandiargues: [email protected] - +33 6 16 16 51 78

AI Terminal

Biophytis S.A.

1153_iss_2025-03-06_85edf8a6-a212-48a2-9415-fbdae20c6c85.pdf